Healthcare > Pharmaceuticals & Biotechnology
•2432 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2432)
| Company | Market Cap | Price |
|---|---|---|
|
BCLI
Brainstorm Cell Therapeutics Inc.
NurOwn is a proprietary autologous cell therapy platform developed by Brainstorm for ALS and related neurodegenerative indications, directly produced and administered by the company.
|
$4.24M |
$0.70
|
|
TTNP
Titan Pharmaceuticals, Inc.
Titan's core ProNeura technology is a long-acting drug delivery platform used for subdermal implants.
|
$4.21M |
$4.61
|
|
CYCN
Cyclerion Therapeutics, Inc.
Cyclerion is centered on neuropsychiatric drug development, specifically an individualized therapy for Treatment Resistant Depression (TRD).
|
$4.14M |
$1.24
-0.40%
|
|
BUDZ
WEED, Inc.
Sangre AgroTech represents plant genomic research services, akin to contract research and development.
|
$4.08M |
$0.03
|
|
MGRX
Mangoceuticals, Inc.
Patented antiviral small-molecule therapeutics (MGX-0024) introduced as an IP asset with clinical development.
|
$4.04M |
$0.39
+2.79%
|
|
SONN
Sonnet BioTherapeutics Holdings, Inc.
Sonnet's core pipeline is oncology-focused immunotherapies (e.g., SON-1010 IL-12) leveraging the FHAB platform.
|
$3.99M |
$1.28
+1.98%
|
|
OGEN
Oragenics, Inc.
ONP-002 uses a proprietary intranasal drug-delivery platform (powder formulation + breath-propelled device).
|
$3.77M |
$0.95
+2.56%
|
|
CLDI
Calidi Biotherapeutics, Inc.
Calidi Biotherapeutics directly develops cancer therapies (oncolytic virus platforms) targeting oncology indications.
|
$3.77M |
$0.77
+4.55%
|
|
LADX
LadRx Corporation
LadRx is a biotechnology company focused on oncology drug development.
|
$3.70M |
$0.11
|
|
ENTO
Entero Therapeutics, Inc.
Adrulipase is a recombinant lipase enzyme produced as a therapeutic for exocrine pancreatic insufficiency, fitting Recombinant Proteins & Enzymes.
|
$3.65M |
$2.96
+22.31%
|
|
BIXT
Bioxytran, Inc.
ProLectin-M is an oral antiviral candidate; fits the Oral Small Molecule Therapeutics category as a major product line.
|
$3.58M |
$0.04
|
|
BIOE
Bio Essence Corporation
Provides outsourced contract manufacturing (OEM) services for health-related products.
|
$3.42M |
$0.09
|
|
BZYR
Burzynski Research Institute, Inc.
Company focuses on oncology therapeutics in biotech R&D.
|
$3.29M |
$0.03
|
|
SILO
Silo Pharma, Inc.
Drug Delivery Platforms directly describes Silo's intranasal and implantable drug delivery technologies (SPC-15, SPC-14, SP-26).
|
$3.28M |
$0.34
-3.64%
|
|
CASI
CASI Pharmaceuticals, Inc.
CID-103 is a monoclonal antibody therapeutic, a core product class for the company.
|
$3.22M |
$0.21
+2.99%
|
|
GOVX
GeoVax Labs, Inc.
GeoVax directly develops and manufactures vaccines using its MVA platform for infectious diseases (Mpox/smallpox and COVID-19 programs).
|
$3.20M |
$3.16
+9.72%
|
|
CANF
Can-Fite BioPharma Ltd.
Company focuses on orally bioavailable small molecule therapeutics targeting A3AR, including Piclidenoson and Namodenoson.
|
$2.99M |
$4.74
-21.26%
|
|
KALA
KALA BIO, Inc.
KPI-012 is a mesenchymal stem cell secretome (MSC-S) therapy, aligning with Biotech - Cell Therapy.
|
$2.67M |
$0.38
-5.27%
|
|
JAGX
Jaguar Health, Inc.
Jaguar Health focuses on crofelemer-based therapies delivered orally, aligning with the Oral Small Molecule Therapeutics category.
|
$2.54M |
$1.18
+3.98%
|
|
AIM
AIM ImmunoTech Inc.
Ampligen is AIM ImmunoTech's flagship oncology/immunotherapy platform and is being developed with cancer indications (pancreatic and ovarian cancer) in combination with checkpoint inhibitors.
|
$2.46M |
$0.91
|
|
ACXP
Acurx Pharmaceuticals, Inc.
Lead product ibezapolstat is an oral small-molecule antibiotic for CDI, aligning with the 'Oral Small Molecule Therapeutics' investable theme.
|
$2.41M |
$1.53
+0.99%
|
|
ERNA
Ernexa Therapeutics Inc.
Lead product is off-the-shelf allogeneic cell therapy using iPSC-derived mesenchymal stem cells (iMSCs).
|
$2.35M |
$0.33
+7.05%
|
|
CARM
Carisma Therapeutics, Inc.
CAR-Macrophage platform is a cell-therapy technology, directly representing Carisma's core product category.
|
$2.33M |
$0.15
+196.92%
|
|
PPCB
Propanc Biopharma, Inc.
Propanc Biopharma is a development-stage biotechnology company focusing on oncology therapies, making PRP its core candidate.
|
$2.29M |
$0.17
+0.17%
|
|
CLSD
Clearside Biomedical, Inc.
Clearside's core offering is a drug delivery platform enabling suprachoroidal (eye) delivery and extended-release formulations.
|
$2.15M |
$0.43
+4.90%
|
|
AAGH
America Great Health
Joint venture and activities in cell therapy and regenerative medicine.
|
$2.12M |
$0.00
|
|
SHPH
Shuttle Pharmaceuticals Holdings, Inc.
Company is a oncology-focused biotech developing radiation sensitizers and HDAC inhibitor therapeutics, with lead assets in Phase 2/preclinical stages.
|
$1.98M |
$1.79
-2.97%
|
|
REVB
Revelation Biosciences, Inc.
Core product focus on modulating innate immunity using the Gemini platform, aligning with Immunology Therapeutics.
|
$1.85M |
$1.22
-2.40%
|
|
YBGJ
Yubo International Biotech Limited
Endometrial stem cell research and potential cell therapies (core biotech focus).
|
$1.77M |
$0.01
|
|
BRTX
BioRestorative Therapies, Inc.
BRTX-100 is an autologous mesenchymal stem cell therapy, the company's lead cell therapy product for disc disease.
|
$1.73M |
$0.22
+0.14%
|
|
BICX
BioCorRx Inc.
BioCorRx is actively commercializing Lucemyra, an FDA-approved oral small molecule therapeutic for opioid withdrawal, expanding direct product sales.
|
$1.69M |
$0.40
|
|
LYRA
Lyra Therapeutics, Inc.
XTreo drug-delivery platform is Lyra's core product, enabling six months of localized drug therapy via in-office implant (LYR-210).
|
$1.66M |
$1.12
|
|
ELAB
PMGC Holdings Inc.
Contract Research Organizations (CRO)-like R&D capabilities through PMGC Research Inc. for biotech development.
|
$1.63M |
$3.35
-13.12%
|
|
SIGY
Sigyn Therapeutics, Inc.
Company’s cancer-related therapeutic platform focus places it in Biotech - Oncology.
|
$1.57M |
$0.05
|
|
ENVB
Enveric Biosciences, Inc.
Enveric is focused on neuropsychiatric drug development with a lead program targeting neuroplasticity-based therapies.
|
$1.45M |
$5.21
-2.71%
|
|
GRTX
Galera Therapeutics, Inc.
Company directly develops oncology therapeutics, including its NOS pan-inhibitor and SOD mimetics for cancer indications.
|
$1.31M |
$0.02
|
|
APVO
Aptevo Therapeutics Inc.
APVO is a oncology-focused biotech developing novel immunotherapies, including mipletamig and other pipelines targeting cancer.
|
$1.23M |
$6.71
-0.30%
|
|
HCWB
HCW Biologics Inc.
HCWB's lead programs target oncology through novel immunotherapies, aligning with Biotech - Oncology.
|
$1.18M |
$0.65
+18.18%
|
|
BIAF
bioAffinity Technologies, Inc.
The business focuses on oncology diagnostics (early detection of lung cancer).
|
$977412 |
$1.07
+3.88%
|
|
NLSP
NLS Pharmaceutics AG
NLSP's lead products Quilience and Nolazol are oral, extended-release small-molecule therapeutics based on mazindol.
|
$894150 |
$0.79
-72.35%
|
Showing page 24 of 25 (2432 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
